Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies

Three closely related molecular human immunodeficiency virus type 1 (HIV-1) clones, with differential neutralization phenotypes, were generated by cloning of an NcoI-BamHI envelope (env) gene fragment (HXB2R nucleotide positions 5221 to 8021) into the full-length HXB2 molecular clone of HIV-1 IIIB. These env gene fragments, containing the complete gp120 coding region and a major part of gp41, were obtained from three different biological clones derived from a chimpanzee-passaged HIV-1 IIIB isolate. Two of the viruses thus obtained (4.4 and 5.1) were strongly resistant to neutralization by infection-induced chimpanzee and human polyclonal antibodies and by HIV-1 IIIB V3-specific monoclonal antibodies and weakly resistant to soluble CD4 and a CD4-binding-site-specific monoclonal antibody. The third virus (6.8) was sensitive to neutralization by the same reagents. The V3 coding sequence and the gp120 amino acid residues important for the discontinuous neutralization epitope overlapping the CD4-binding site were completely conserved among the clones. However, the neutralization-resistant clones 4.4 and 5.1 differed from neutralization-sensitive clone 6.8 by two mutations in gp41. Exchange experiments confirmed that the 3' end of clone 6.8 (nucleotides 6806 to 8021; amino acids 346 to 752) conferred a neutralization-sensitive phenotype to both of the neutralization-resistant clones 4.4 and 5.1. From our study, we conclude that mutations in the extracellular portion of gp41 may affect neutralization sensitivity to gp120 antibodies.

[1]  R. Weiss,et al.  Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. , 1989, The Journal of general virology.

[2]  C. Debouck,et al.  Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1 , 1990, Journal of medical virology.

[3]  J. Albert,et al.  Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. , 1991, Virology.

[4]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[5]  J. Goudsmit,et al.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity , 1992, Journal of virology.

[6]  J. Sodroski,et al.  Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. , 1993, AIDS.

[7]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[8]  M. Wainberg,et al.  Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. , 1990, The Journal of infectious diseases.

[9]  M. Uhlén,et al.  Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. , 1991, AIDS research and human retroviruses.

[10]  R. F. Smith,et al.  Human retroviruses and aids, 1992 , 1992 .

[11]  S. Zolla-Pazner,et al.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro , 1991, Journal of virology.

[12]  M. Reitz,et al.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene , 1988, Cell.

[13]  E K Ross,et al.  Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[14]  R. Meloen,et al.  Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1. , 1991, The Journal of general virology.

[15]  M. Reitz,et al.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope , 1990, Journal of virology.

[16]  S. Zolla-Pazner,et al.  Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. , 1990, Journal of immunology.

[17]  Y. Masuho,et al.  Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. , 1991, Virology.

[18]  J. Goudsmit,et al.  Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. , 1988, Vaccine.

[19]  R. Gallo,et al.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees , 1990, Journal of virology.

[20]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[21]  J. Goudsmit,et al.  Association of antibodies blocking HIV‐1 gp160‐sCD4 attachment with virus neutralizing activity in human sera , 1990, Journal of medical virology.

[22]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[23]  B. Cullen,et al.  Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. , 1992, Science.

[24]  L. Arthur,et al.  Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses , 1987, Journal of virology.

[25]  S. Jiang,et al.  Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1). , 1992, Virology.

[26]  W. O'brien,et al.  HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain , 1990, Nature.

[27]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.